Marta Figueiredo, PhD, science writer —

Marta holds a biology degree, a master’s in evolutionary and developmental biology, and a PhD in biomedical sciences from the University of Lisbon, Portugal. She was awarded a research scholarship and a PhD scholarship, and her research focused on the role of several signaling pathways in thymus and parathyroid glands embryonic development. She also previously worked as an assistant professor of an annual one-week embryology course at the University of Lisbon’s Faculty of Medicine.

Articles by Marta Figueiredo

Patterns in HRCT Lung Scans May Predict Survival Rates in IPAH

The presence of specific patterns called centrilobular ground-glass opacifications (cGGOs) in high-resolution computed tomography (HRCT) lung scans is associated with a two-year higher risk of death in people with idiopathic pulmonary arterial hypertension (IPAH), according to a small study in Poland. These findings suggest that chest HRCT data could…

Benefits of PTE Surgery for CTEPH Rapid and Sustained, Study Shows

Pulmonary thromboendarterectomy (PTE) quickly and significantly improved blood flow dynamics and right-sided heart function in people with chronic thromboembolic pulmonary hypertension (CTEPH), with the surgery’s benefits sustained over the long term, a small study shows. Notably, right ventricular (RV) free wall strain, an indirect and non-invasive measure of…

Worse Quality of Life, More Hospitalizations in CTEPH vs. IPAH

People with chronic thromboembolic pulmonary hypertension (CTEPH) have significantly worse quality of life at their initial assessment, and higher hospitalization rates over time, relative to idiopathic pulmonary arterial hypertension (IPAH) patients, according to a multicenter study in the U.S. Notably, these quality-of-life differences disappeared over time, and CTEPH…

Arterial Stiffness Early Marker of CTEPH After Embolism

In people experiencing a pulmonary embolism, higher-than-normal arterial stiffness at the time of hospital discharge increased the risk of pulmonary arterial hypertension (PAH) when evaluated one month later, according to a study in Italy. Given that this patient population is at risk of chronic thromboembolic pulmonary hypertension…

CIT GAP Funds Invests in OxiWear Device for PH Patients

The Center for Innovative Technology (CIT) GAP Funds has invested in OxiWear and its ear-wearable device designed to continuously monitor blood oxygen levels in people with pulmonary hypertension (PH) and alert them when levels fall below safe thresholds. Oxiwear is expected to help patients get the help they…

Research Sheds Light on Potential Immune Changes in IPAH

A combination of lung injury and increased activation of B-cells — immune cells responsible for antibody production — was sufficient to promote symptoms of pulmonary hypertension (PH) in mice, a study shows. In addition, increased B-cell activation and higher levels of immune cells known to promote antibody production also were…

Text-based Intervention Helped Increase Physical Activity

A three-month unsupervised health intervention based on a commercial activity tracker and motivational texts significantly increased daily step counts and improved quality of life in adults with pulmonary arterial hypertension (PAH), according to data from a single-center trial in the U.S. Since physical activity has been shown to…

Tyvaso Becomes 1st PH-ILD Treatment Approved in US

Tyvaso (inhaled treprostinil) has become the first treatment approved in the U.S. for people with pulmonary hypertension associated with interstitial lung disease (PH-ILD). The U.S. Food and Drug Administration (FDA) approved Tyvaso, developed by United Therapeutics, to improve exercise ability in PH-ILD patients, the company said. “The…